GCM
PRLD icon

Graham Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Graham Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$159K Buy
29,770
+18,427
+162% +$80.2K ﹤0.01% 1083
2026
Q1 		$38.8K Buy
+11,343
New +$29.7K ﹤0.01% 1100

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Graham Capital Management's PRLD Position: Q2 2026 in Review

Graham Capital Management increased its Prelude Therapeutics (PRLD) stake by 162% in Q2 2026, buying an estimated $80.2K and bringing the position to 29,770 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #1083.

Graham Capital Management first reported a position in PRLD in Q1 2026 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Graham Capital Management held 29,770 shares of Prelude Therapeutics worth $159K as of Q2 2026.
  • Graham Capital Management bought 18,427 Prelude Therapeutics shares in Q2 2026, an estimated $80.2K.
  • Prelude Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1083 holding.
  • Graham Capital Management first reported a position in Prelude Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.